Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments.

Maiti P, Manna J, Dunbar GL.

Transl Neurodegener. 2017 Oct 25;6:28. doi: 10.1186/s40035-017-0099-z. eCollection 2017. Review.

2.

Comorbidity burden of patients with Parkinson's disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China.

Wang X, Zeng F, Jin WS, Zhu C, Wang QH, Bu XL, Luo HB, Zou HQ, Pu J, Zhou ZH, Cui XP, Wang QS, Shi XQ, Han W, Wu Q, Chen HS, Lin H, Zhang LL, Zhang M, Lian Y, Xu ZQ, Zhou HD, Zhang T, Wang YJ.

Sci Rep. 2017 May 10;7(1):1671. doi: 10.1038/s41598-017-01795-0.

3.

Neuropsychiatric characteristics of GBA-associated Parkinson disease.

Swan M, Doan N, Ortega RA, Barrett M, Nichols W, Ozelius L, Soto-Valencia J, Boschung S, Deik A, Sarva H, Cabassa J, Johannes B, Raymond D, Marder K, Giladi N, Miravite J, Severt W, Sachdev R, Shanker V, Bressman S, Saunders-Pullman R.

J Neurol Sci. 2016 Nov 15;370:63-69. doi: 10.1016/j.jns.2016.08.059. Epub 2016 Aug 30.

4.

Whole-Exome Sequencing in Familial Parkinson Disease.

Farlow JL, Robak LA, Hetrick K, Bowling K, Boerwinkle E, Coban-Akdemir ZH, Gambin T, Gibbs RA, Gu S, Jain P, Jankovic J, Jhangiani S, Kaw K, Lai D, Lin H, Ling H, Liu Y, Lupski JR, Muzny D, Porter P, Pugh E, White J, Doheny K, Myers RM, Shulman JM, Foroud T.

JAMA Neurol. 2016 Jan;73(1):68-75. doi: 10.1001/jamaneurol.2015.3266.

5.

Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease.

Chege PM, McColl G.

Front Aging Neurosci. 2014 May 19;6:89. doi: 10.3389/fnagi.2014.00089. eCollection 2014. Review.

6.

Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

Barrett MJ, Shanker VL, Severt WL, Raymond D, Gross SJ, Schreiber-Agus N, Kornreich R, Ozelius LJ, Bressman SB, Saunders-Pullman R.

JIMD Rep. 2014;16:31-8. doi: 10.1007/8904_2014_315. Epub 2014 May 22.

7.

Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?

Heller J, Dogan I, Schulz JB, Reetz K.

Aging Dis. 2013 Oct 22;5(1):63-75. doi: 10.14366/AD.2014.050063. eCollection 2014 Feb. Review.

8.

Parkinson disease loci in the mid-western Amish.

Davis MF, Cummings AC, D'Aoust LN, Jiang L, Velez Edwards DR, Laux R, Reinhart-Mercer L, Fuzzell D, Scott WK, Pericak-Vance MA, Lee SL, Haines JL.

Hum Genet. 2013 Nov;132(11):1213-21. doi: 10.1007/s00439-013-1316-1. Epub 2013 Jun 21.

9.

Genetic basis of Parkinson's disease: inheritance, penetrance, and expression.

Schulte C, Gasser T.

Appl Clin Genet. 2011 Jun 1;4:67-80. doi: 10.2147/TACG.S11639. Print 2011.

10.

Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide.

Morrison BE, Marcondes MC, Nomura DK, Sanchez-Alavez M, Sanchez-Gonzalez A, Saar I, Kim KS, Bartfai T, Maher P, Sugama S, Conti B.

J Immunol. 2012 Dec 15;189(12):5498-502. doi: 10.4049/jimmunol.1102150. Epub 2012 Nov 19.

11.

Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease.

Barrett MJ, Hagenah J, Dhawan V, Peng S, Stanley K, Raymond D, Deik A, Gross SJ, Schreiber-Agus N, Mirelman A, Marder K, Ozelius LJ, Eidelberg D, Bressman SB, Saunders-Pullman R; LRRK2 Ashkenazi Jewish Consortium.

Parkinsonism Relat Disord. 2013 Feb;19(2):186-91. doi: 10.1016/j.parkreldis.2012.09.007. Epub 2012 Oct 10.

12.

Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA.

Horm Behav. 2013 Feb;63(2):308-14. doi: 10.1016/j.yhbeh.2012.05.013. Epub 2012 Jun 8.

13.

Genetics of Parkinson's disease.

Gasser T.

Dialogues Clin Neurosci. 2004 Sep;6(3):295-301.

14.

Olfactory dysfunction in LRRK2 G2019S mutation carriers.

Saunders-Pullman R, Stanley K, Wang C, San Luciano M, Shanker V, Hunt A, Severt L, Raymond D, Ozelius LJ, Lipton RB, Bressman SB.

Neurology. 2011 Jul 26;77(4):319-24. doi: 10.1212/WNL.0b013e318227041c. Epub 2011 Jul 13.

15.

Gender differences in the risk of familial parkinsonism: beyond LRRK2?

Saunders-Pullman R, Stanley K, San Luciano M, Barrett MJ, Shanker V, Raymond D, Ozelius LJ, Bressman SB.

Neurosci Lett. 2011 Jun 1;496(2):125-8. doi: 10.1016/j.neulet.2011.03.098. Epub 2011 Apr 12.

16.

LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.

Saunders-Pullman R, Barrett MJ, Stanley KM, Luciano MS, Shanker V, Severt L, Hunt A, Raymond D, Ozelius LJ, Bressman SB.

Mov Disord. 2010 Nov 15;25(15):2536-41. doi: 10.1002/mds.23314.

17.

Parkinson's disease candidate gene prioritization based on expression profile of midbrain dopaminergic neurons.

Vahedi S, Rajabian M, Misaghian A, Grbec D, Simon HH, Alavian KN.

J Biomed Sci. 2010 Aug 17;17:66. doi: 10.1186/1423-0127-17-66.

18.

A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity.

Poorkaj P, Raskind WH, Leverenz JB, Matsushita M, Zabetian CP, Samii A, Kim S, Gazi N, Nutt JG, Wolff J, Yearout D, Greenup JL, Steinbart EJ, Bird TD.

Mov Disord. 2010 Jul 30;25(10):1409-17. doi: 10.1002/mds.23085.

19.

Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization.

Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S, Tagliati M, Condefer K, Palmese C, Brüggemann N, Klein C, Roe A, Kornreich R, Ozelius L, Bressman S.

Mov Disord. 2010 Jul 30;25(10):1364-72. doi: 10.1002/mds.23046.

20.

Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease.

Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Nichols WC, Foroud T; Parkinson Study Group-PROGENI Investigators.

BMC Med Genet. 2010 Apr 1;11:53. doi: 10.1186/1471-2350-11-53.

Supplemental Content

Support Center